Form 4: Sage Therapeutics Director James Frates Awarded Stock Options

Director James M Frates received stock options from Sage Therapeutics under the company's 2024 Equity Incentive Plan.

Summary

• James M Frates, a director of Sage Therapeutics, was granted stock options on June 10, 2024.
• The options, totaling 12,500 shares, were awarded under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.
• The exercise price of the options is $10.90 per share.
• The options will vest on the earlier of June 10, 2025, or the day before the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• The options expire on June 9, 2034.
• Brandon Marsh, acting as Attorney-in-Fact, signed the Form 4 on behalf of James M Frates.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of compensating directors with stock options, which is generally viewed positively as it aligns interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, performance, and board structure.
• Companies like Biogen and Vertex Pharmaceuticals also utilize stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical components of such grants, designed to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director benefits from the potential increase in the value of the stock.

Key Dates